Wundinfektionen – Infektionsprävention in Unfallchirurgie und Orthopädie

Seifert, Julia; Gümbel, Denis; Frank, Matthias; Krämer, Axel

doi:10.1055/s-0043-105464

Cited by 1 publication

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To eliminate the resident skin flora as the major source of SSI, the focus is on the following measures: pre-surgical antiseptic washing, if needed preoperative decolonization of S. aureus , deep skin antisepsis [ 14 ], antiseptic irrigation of the surgical field before suturing [ 15 ], glove change before inserting the sterile implant [ 16 ], biofilm reducing wound closure [ 17 ], antiseptic suture material [ 18 ], and perioperative parenteral antibiotic prophylaxis [ 19 , 20 ]. Due to the prevalence of SSI and the resulting high costs, every effort must be made to reduce the SSI rate.…”

Section: Introductionmentioning

confidence: 99%

Advanced Skin Antisepsis: Application of UVA-Cleavable Hydroxyethyl Starch Nanocapsules for Improved Eradication of Hair Follicle-Associated Microorganisms

et al. 2023

Self Cite

View full text Add to dashboard Cite

Hair follicles constitute important drug delivery targets for skin antisepsis since they contain ≈25% of the skin microbiome. Nanoparticles are known to penetrate deeply into hair follicles. By massaging the skin, the follicular penetration process is enhanced based on a ratchet effect. Subsequently, an intrafollicular drug release can be initiated by various trigger mechanisms. Here, we present novel ultraviolet A (UVA)-responsive nanocapsules (NCs) with a size between 400 and 600 nm containing hydroxyethyl starch (HES) functionalized by an o-nitrobenzyl linker. A phase transfer into phosphate-buffered saline (PBS) and ethanol was carried out, during which an aggregation of the particles was observed by means of dynamic light scattering (DLS). The highest stabilization for the target medium ethanol as well as UVA-dependent release of ethanol from the HES-NCs was achieved by adding 0.1% betaine monohydrate. Furthermore, sufficient cytocompatibility of the HES-NCs was demonstrated. On ex vivo porcine ear skin, a strong UVA-induced release of the model drug sulforhodamine 101 (SR101) could be demonstrated after application of the NCs in cyclohexane using laser scanning microscopy. In a final experiment, a microbial reduction comparable to that of an ethanol control was demonstrated on ex vivo porcine ear skin using a novel UVA-LED lamp for triggering the release of ethanol from HES-NCs. Our study provides first indications that an advanced skin antisepsis based on the eradication of intrafollicular microorganisms could be achieved by the topical application of UVA-responsive NCs.

show abstract